Logo

NNNN

Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares • NASDAQ
$23.57 ▲ 4.34% (+0.98)
Market Cap $1.03 B
52w High $55.65
52w Low $5.18
Dividend Yield 0%
P/E 392.83
Volume 22.31K
Outstanding Shares 43.89M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $2.528M ▼ $3.873M ▲ $-1.325M ▼ -52.4% ▼ $-0.031 ▼ $-1.325M ▼
Q2-2024 $6.323M ▲ $337.502K ▼ $3.887M ▲ 61.485% ▲ $0.092 ▲ $3.887M ▲
Q4-2023 $3.951M ▲ $1.108M ▲ $792.932K ▼ 20.071% ▼ $0.019 ▼ $796.474K ▼
Q2-2023 $3.306M $406.055K $1.643M 49.701% $0.039 $1.653M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $11.761M ▲ $18.922M ▼ $1.73M ▲ $17.192M ▼
Q2-2024 $10.31M ▲ $18.943M ▲ $527.753K ▼ $18.415M ▲
Q4-2023 $9.688M ▼ $15.812M ▲ $993.06K ▼ $14.819M ▲
Q2-2023 $10.561M ▲ $15.427M ▲ $1.342M ▼ $14.086M ▲
Q4-2022 $8.669M $13.958M $1.411M $12.547M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-1.325M ▼ $1.604M ▲ $215.569K ▲ $-248.893K ▼ $0 $1.604M ▲
Q2-2024 $3.887M ▲ $647.539K ▲ $149.344K ▼ $-124.142K ▼ $0 $647.54K ▲
Q4-2023 $792.932K ▼ $-1.332M ▼ $160.696K ▼ $230.082K ▲ $0 $-1.332M ▼
Q2-2023 $1.643M $2.303M $1.711M $-276.414K $0 $2.303M

Five-Year Company Overview

Income Statement

Income Statement NNNN is still at a very early, almost pilot scale of operations. Revenue exists but is tiny, and it has only recently started to show modest profitability on paper. The good news is that costs seem reasonably controlled and the business is not burning large amounts of money relative to its size. The flip side is that, at this stage, the income statement tells more of a “prototype and rollout” story than a mature, stable business; small changes in sales or costs could swing results quite easily.

Balance Sheet

Balance Sheet The balance sheet is light and simple, reflecting a young company. Assets and equity have been building gradually, helped by the absence of financial debt, which reduces balance sheet risk. Cash balances are small but meaningful relative to the current scale of the business. Overall, the company looks conservatively financed, but also still quite small and likely reliant on future growth, funding, or partnerships to scale up meaningfully.

Cash Flow

Cash Flow Reported operating and free cash flow are essentially flat, suggesting that cash movements so far have been limited or are not yet very informative at this scale. The business does not appear to be heavily investing in physical assets yet, which fits a technology- and IP-driven model. The key cash-flow questions going forward will be how quickly commercial adoption ramps up and whether additional capital will be needed to fund global expansion and regulatory work.

Competitive Edge

Competitive Edge NNNN is aiming to differentiate itself in the diagnostics space through decentralization: tests that can be run quickly, closer to patients, instead of relying solely on central labs. Its broad platform coverage (PCR, chemiluminescence, rapid tests, and more) and dual focus on human and veterinary health give it multiple ways to compete. The main challenge is that it operates in a field dominated by large, established players with strong brands and deep customer relationships, so execution speed, niche focus, and regulatory success will be critical to carving out a durable position.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of NNNN’s story. The ultra-fast PCR system and dry-chemiluminescence platform show a strong push toward faster, more convenient, and logistically simpler testing. Features like extraction-free PCR, freeze‑dried reagents that don’t require cold storage, and point‑of‑care designs all target real pain points in diagnostics, especially in resource‑limited or decentralized settings. The company’s pipeline, including planned tests for diseases like TB and HPV and continued work on dry reagent technology, underscores a forward‑leaning R&D posture, though commercial success and regulatory approvals remain key uncertainties.

Summary

NNNN looks like a classic early‑stage, innovation‑driven diagnostics company: financially small, relatively clean and low‑debt, and still in the early innings of commercialization. Its main strengths lie in novel technologies, speed to market, and a product strategy built around decentralized and point‑of‑care testing across multiple platforms and disease areas. The main risks are its tiny current scale, the intensity of competition from much larger diagnostics players, and the uncertainty around how quickly it can convert its innovation pipeline into broad, profitable adoption. For now, NNNN is best understood as a high‑innovation, early‑development story rather than a mature, steady‑state healthcare business.